Oct 2026· Journal of Affective Disorders· Vol 417, pp.
122671
· 0 citations· 51 references
Medicine
TL;DR
ECT was associated with a statistically significant improvement in anhedonia among adults with MDD, and future ECT studies should assess anhedonia as an outcome, while using a validated anhedonia measure.
Abstract
Background
Anhedonia is a core symptom of major depressive disorder (MDD) and may persist despite otherwise effective treatment. Electroconvulsive therapy (ECT) is a widely used and effective intervention for severe and treatment-resistant depression, however, its specific effects on anhedonia remain poorly characterized.
Objective
To conduct a systematic review and meta-analysis examining ECT-associated changes in anhedonia in adults with MDD.
Methods
A systematic search was conducted across Embase, MEDLINE, PsycINFO, and Scopus. Studies were eligible if they included adults with MDD, administered ECT as a treatment, and assessed anhedonia using a validated scale. Standardized mean change ratios (SMCs) were calculated and pooled using a random-effects model.
Results
Eleven studies were included in the systematic review, of which five provided quantitative data for meta-analysis. Across 132 participants, ECT was associated with a significant improvement in anhedonia severity (SMC = 1.02; 95% CI, 0.63-1.42).
Conclusions
ECT was associated with a statistically significant improvement in anhedonia among adults with MDD. However, given the small number of included studies and non-randomized pre-post designs, these findings should be interpreted cautiously. Future ECT studies should assess anhedonia as an outcome, while using a validated anhedonia measure.
BACKGROUND
Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in major depressive disorder (MDD), however, its effects on anhedonia specifically have yet to be...
Erica S. Kaczmarek, Sabrina Wong, Noah Chisamore et al.· Journal of Psychiatric Resea...· 0 citations
Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients’ quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored.
In this study, a prosp...
Qian-Qian Wu, Wei-Cheng Li, Zhan-Jie Luo et al.· BMC Psychiatry· 0 citations
Objective: Treatment-resistant depression (TRD) is a severe form of major depressive disorder (MDD) associated with increased suicidality. Anhedonia, the reduced ability to experience pleasure, is recognized across various psychiatric conditions, including TRD. This study aims to investigate the relationship between ch...
T. Sternat, I. Epstein, K. Fotinos et al.· Journal of Clinical Psychiat...· 0 citations
Introduction: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and accounts for disproportionate disability and mortality. Electroconvulsive therapy (ECT) has long been the definitive intervention, whereas subanaesthetic intravenous ketamine has emerged as...
Arby Shafara Sekundaputra, Rahmawati· International journal of med...· 0 citations
Approximately half of children with anxiety disorder(s) or obsessive-compulsive disorder (OCD) derive insufficient benefit from first-step evidence-based treatments, including cognitive behavioural therapy (CBT) and pharmacotherapy. Few studies have examined second-step treatment options, and clinical guidelines offer...
Colin O. W. Ganzevoort, Rianne Hornstra, L. Wolters et al.· European Child and Adolescen...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.